Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

New and Effective Inhibitor of Class I HDACs, Eimbinostat, Reduces the Growth of Hematologic Cancer Cells and Triggers Apoptosis

Spirin, Pavel ; Vedernikova, Valeria ; Volkava, Tatsiana ; Morozov, Alexey ; Kleymenova, Alla ; Zemskaya, Anastasia ; Shyrokova, Lena LU orcid ; Porozov, Yuri ; Glumakova, Ksenia and Lebedev, Timofey , et al. (2025) In Pharmaceutics 17(4).
Abstract

Background: Histone deacetylases (HDACs) are critical epigenetic modulators involved in regulating various molecular mechanisms essential for cell development and growth. Alterations in HDAC activity have been linked to the progression of numerous cancers, including lymphoma. Over the past decade, the FDA has approved several HDAC inhibitors for lymphoma treatment, leading to heightened interest in this emerging class of drugs. Methods: In our research, we developed a novel HDAC inhibitor that exhibits high selectivity for class I HDACs. Results: Our in vitro findings indicate that treating lymphoma/leukemia cells with this inhibitor results in a marked suppression of cell growth and promotes apoptosis, while leaving the cell cycle... (More)

Background: Histone deacetylases (HDACs) are critical epigenetic modulators involved in regulating various molecular mechanisms essential for cell development and growth. Alterations in HDAC activity have been linked to the progression of numerous cancers, including lymphoma. Over the past decade, the FDA has approved several HDAC inhibitors for lymphoma treatment, leading to heightened interest in this emerging class of drugs. Methods: In our research, we developed a novel HDAC inhibitor that exhibits high selectivity for class I HDACs. Results: Our in vitro findings indicate that treating lymphoma/leukemia cells with this inhibitor results in a marked suppression of cell growth and promotes apoptosis, while leaving the cell cycle unaffected. Conclusions: We propose that our new inhibitor, named eimbinostat, holds significant promise as a potential therapeutic agent for the treatment of hematologic malignancies such as lymphoma or leukemia.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
apoptosis, belinostat, cell cycle, epigenetic, HDACs, leukemia, lymphoma
in
Pharmaceutics
volume
17
issue
4
article number
416
publisher
MDPI AG
external identifiers
  • scopus:105003552914
  • pmid:40284412
ISSN
1999-4923
DOI
10.3390/pharmaceutics17040416
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 by the authors.
id
57d04857-26be-4d42-8729-361d08f88439
date added to LUP
2025-08-12 10:13:22
date last changed
2025-08-13 03:00:09
@article{57d04857-26be-4d42-8729-361d08f88439,
  abstract     = {{<p>Background: Histone deacetylases (HDACs) are critical epigenetic modulators involved in regulating various molecular mechanisms essential for cell development and growth. Alterations in HDAC activity have been linked to the progression of numerous cancers, including lymphoma. Over the past decade, the FDA has approved several HDAC inhibitors for lymphoma treatment, leading to heightened interest in this emerging class of drugs. Methods: In our research, we developed a novel HDAC inhibitor that exhibits high selectivity for class I HDACs. Results: Our in vitro findings indicate that treating lymphoma/leukemia cells with this inhibitor results in a marked suppression of cell growth and promotes apoptosis, while leaving the cell cycle unaffected. Conclusions: We propose that our new inhibitor, named eimbinostat, holds significant promise as a potential therapeutic agent for the treatment of hematologic malignancies such as lymphoma or leukemia.</p>}},
  author       = {{Spirin, Pavel and Vedernikova, Valeria and Volkava, Tatsiana and Morozov, Alexey and Kleymenova, Alla and Zemskaya, Anastasia and Shyrokova, Lena and Porozov, Yuri and Glumakova, Ksenia and Lebedev, Timofey and Kozlov, Maxim and Prassolov, Vladimir}},
  issn         = {{1999-4923}},
  keywords     = {{apoptosis; belinostat; cell cycle; epigenetic; HDACs; leukemia; lymphoma}},
  language     = {{eng}},
  number       = {{4}},
  publisher    = {{MDPI AG}},
  series       = {{Pharmaceutics}},
  title        = {{New and Effective Inhibitor of Class I HDACs, Eimbinostat, Reduces the Growth of Hematologic Cancer Cells and Triggers Apoptosis}},
  url          = {{http://dx.doi.org/10.3390/pharmaceutics17040416}},
  doi          = {{10.3390/pharmaceutics17040416}},
  volume       = {{17}},
  year         = {{2025}},
}